Diverse Biotech announces paper publication on new Gene Expression for the forthcoming BIO Meet

News provided by

News Updates on Industries

Feb 17, 2020, 19:30 EST

Feb 17, 2020, 19:30 /Comserve / -- The announcement was made by Diverse Biotech, Inc. about its selection for presenting paper for the upcoming BIO CEO and Investor Conference that would be held on February 11, 2020 in New York.

Image placeholder

Diverse Biotech, Inc., one of the companies engaged in clinical-stage biopharmaceutical research announced that they have been chosen for submission at the forthcoming BIO CEO and Investor Conference which would be taking place at New York on February 11, 2020.

Diverse Biotech has announced further that the work of the company on a paper concerning cannabinoid-related gene expression had been accepted by the Journal of Applied Cell Biology. The publication of paper is expected to be made over the next few weeks.

Stella Vnook, the Chief Executive Officer of Diverse Biotech mentioned that the company is delighted about the fact that they would be having more discussions on their ground breaking technology. Moreover, she added that the gene expression paper was immense, owing to the fact that it has been able to point to a diverse set of cell lines that include glioblastoma, melanoma, actinic keratosis and a few others. All the express genes are pointing to the fact that they would be receptive to exogenous cannabinoid treatment.

About Diverse Biotech

Diverse Biotech, one of the Bio-pharmaceutical companies based in the U.S., has been laying its focus towards medical discoveries, including developing new molecules for treating cancer and other diseases that lower the strength of the body. The focus of Diverse Biotech has been towards discovery and development of novel therapeutics by using cannabidiol (CBD) as the main component, that includes joining them by using highly advanced chemistry along with other molecules in order to develop fresh set of chemical entities that are theoretically effective as well as containing lower levels of poison. The company has been focusing more on hard to treat oncologic disorders, apart from cancers associated with dermatology and pancreatic cancers, as the associated therapies that were targeted have only failed, giving rise to higher unmet needs.   

Independent Writer

For more information, please contact:

Jackie Hurtado

News Updates on Industries
Email: jackiehurtado483@gmail.com
Tel: +1-612-695-8655

Related Links

Also from this source

Kevin Zwick joins ExchangeRight’s Sales Team as Co-Director of National Accounts

ExchangeRight has officially announced the appointment of Kevin Zwick, a former head of sales at Wea

Bioinvent Enters Into Collaboration With Pfizer To Select Second Target For Cancer Immunotherapy Research

The company announced that the second target has been selected by Pfizer under their research partne


More news releases in similar topics